Cost-effectiveness analysis of maintenance agonist treatments in the NEPOD

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 6, Issue 4, 2006, Pages 437-446

  Doran, Christopher M ^a   Shanahan, Marian ^b   Digiusto, Erol ^c   O'Brien, Susannah ^b   Mattick, Richard P ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Cost effectiveness; Health economics; Heroin; NEPOD; Opioid dependence; Pharmacotherapy

Indexed keywords

BUPRENORPHINE; LEVACETYLMETHADOL; METHADONE;

ARTICLE; AUSTRALIA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE REGIMEN; HEALTH CARE POLICY; HEALTH ECONOMICS; HEROIN DEPENDENCE; HOSPITAL PATIENT; HUMAN; MAINTENANCE THERAPY; OPIATE ADDICTION; OUTPATIENT; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 33748111318     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.6.4.437     Document Type: Article

References (43)

1. United Nations International Drug Control Programme (UNIDCP). World Drug Report. Oxford University Press, NY, USA (2001).
2. World Health Organisation. World Health Report 2002: Reducing Risks And Promoting Healthy Life. World Health Organisation, Geneva, Switzerland (2002).
3. Mathers CD, Vos ET, Stevenson CE, Begg SJ. The burden of disease and injury in Australia, Bulletin WHO79, 1076-1084 (2001).
4. Hall W, Ross J, Lynskey M, Law M, Degenhardt L. How many dependent opioid users are there in Australia? In: National Drug and Alcohol Research Centre Monograph Series 44. National Drug and Alcohol Research Centre, Sydney, Australia (2000).
5. National Drug Strategy Household Survey - First Results. Drug Statistics Series No. 13. Australian Institute of Health and Welfare. (AIHW), Canberra, Australia AIHW Cat. No. PHE 57 (2005).
6. Vlahov D, Wang C, Galai N. Mortality risk among new onset injection drug users. Addiction 99, 946-954 (2004).
7. Darke S, Ross J. Suicide among heroin users: rates, risk factors and methods. Addiction 97, 1383-1394 (2002).
8. Ball JC, Shaffer JW, Nurco DN. The day-to-day criminality of heroin addicts in Baltimore: a study in the continuity of offence rates. Drug Alcohol Depend. 12, 119-142 (1983).
9. Digiusto E, Shakeshaft A, Mattick RP, NEPOD Research Group. Effects of Pharmacotherapies for Opioid Dependence on Participants' Criminal Behaviour and Expenditure on Illicit Drugs: an Australian National Evaluation (NEPOD). Australian NZ J Criminology. (2006).
10. Ball JC, Ross A. The Effectiveness of Methadone Maintenance Treatment: Patients, Programs, Services and Outcomes. Springer-Verlag, NY, USA (1991).
11. Hall W, Bell J, Carless J. Crime and drug use among applicants for methadone maintenance. Drug Alcohol Depend.31, 123-129 (1993).
12. UNDCP. Economic and Social Consequences of Drug Abuse and Illicit Trafficking. United Nations Drug Control Program Vienna, Austria (1998).
13. Collins DJ, Lapsley H. Counting the cost: estimates of the social costs of drug abuse in Australia in 1998-99. National Drug Strategy Monograph Series No. 49. Canberra, Commonwealth of Australia (2002).
14. Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J. Subst. Abuse Treat. 28, 321-329 (2005).
15. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Porgrammes. Oxford University Press, Oxford, UK (1987).
16. Doran CM, Shanahan M, Mattick RP, Ali R, White J, Bell J. Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. Drug Alcohol Depend.71, 295-302 (2003).
17. Barnett PG. The cost-effectiveness of methadone maintenance as a health care intervention. Addiction 94, 479-488 (1999).
18. Barnett PG, Zaric GS, Brandeau ML. The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. Addiction 96, 1267-1278 (2001).
19. Zaric GS, Barnett PG, Brandeau ML. HIV transmission and the cost-effectiveness of methadone maintenance. Am. J. Public Health 90, 1100-1111 (2000).
20. Cartwright WS. Cost-benefit Analysis of drug treatment services: review of the literature. J. Mental Health Policy Econ. 3, 11-26 (2000).
21. Mattick RP, Digiusto E, Doran CMet al. National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Commonwealth Department of Health and Ageing, Canberra, Australia (2001).
22. Digiusto E, Mattick RP, Kimber Jet al. National Evaluation of Pharmacotherapies for Opioid Dependence - Why have we done it? Drug Alcohol Rev. 20, 139-141 (2001).
23. Shanahan MD, Doran CM, Digiusto Eet al. A cost-effectiveness analysis of heroin detoxification methods in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addict. Behav., 31(3), 371-387 (2006).
24. Mattick RP, Ali R, White J, O'Brien S, Wolk S, Danz C. Buprenorphine versus methadone maintenance treatment: a randomised double-blind trial with 405 opioid dependant patients. Addiction 98, 441-452 (2003).
25. Lintzeris N, Ritter A, Panjari M, Clark N, Kutin J, Bammer G. Implementing buprenorphine treatment in community settings in Australia: experiences from the Buprenorphine Implementation Trial. Am. J. Addictions 13, S29-S41 (2004).
26. Harris AH, Gospodarevskaya E, Ritter A. A randomised trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting. Pharmacoeconomics 23, 77-91 (2005).
27. Ritter A, Lintzeris N, Clark N, Panjari M, Kutin J, Bammer G. A randomised trial comparing levo-alpha acetylmethadol with methadone maintenance for patients in primary care settings in Australia. Addiction 98, 1065-1113 (2003).
28. Ward J, Mattick RP, Hall W. Methadone Maintenance Treatment and Other Opioid Replacement Therapies. Harwood Press, London, UK (1998)
29. Commonwealth Department of Health and Family Services. Medicare Benefits Schedule. Australian Government Publishing Service, Canberra, Australia (2001).
30. Commonwealth of Australia. Schedule of Pharmaceutical Benefits For Approved Pharmacists and Medical Practitioners, Australian Government Publishing Service, Canberra, Australia (2005).
31. MediMedia. MIMS Annual 2001. MediMedia, St Leonards, Australia (2001).
32. Australian Bureau of Statistics. Consumer Price Index. Cat. No. 6401. ABS Canberra, Australia (2001).
33. British Medical Association. British National Formulary. British Medical Association and the Royal Pharmaceutical Society of Great Britain, London, UK (2002).
34. OECD. Main Economic Indicators - Purchasing Power Parities.OECD, Paris, France (2001).
35. SPSS Institute Inc. Statistical Packages For the Social Sciences. Prentice Hall, Chicago, IL, USA (2004).
36. Briggs A. Handling uncertainty in economic evaluation and presenting the results. In: Economic Evaluation In Health Care: Merging Theory with PracticeDrummond MF, McGuire A, eds.. Oxford University Press, NY, USA, (2001).
37. Efron B, Tibshirani RJ. An introduction to the bootstrap. Monographs on Statistics and Applied Probability. Chapman and Hall, NY, USA (1993).
38. Maisto SA, McKay JR, Connors GJ. Self-report issues in substance abuse: State of the art and future directions. Behav. Asess. 12, 117-134 (1990).
39. Kokkevi A, Richardson C, Palermou B, Leventakou V. Reliability of drug dependents' self-reports. Drug Alcohol Depend. 45, 165-167 (1998).
40. Longshore D, Annon J. Anglin MD, Rawson R. Levo-alpha-acetylmethadol (LAAM) versus methadone: treatment retention and opiate use. Addiction 100, 1131-1139 (2005).
41. US Food and Drug Administration. Product discontinuation notice NDC 0054-3649-63 (August 23) (2003).
42. Doran CM. Buprenorphine, buprenorphine/naloxone and methadone maintenance: a cost-effectiveness analysis. Expert Rev Tharmacoeconomics Outcomes Research 5, 583-592 (2005).
43. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Substance Abuse and Mental Health Services Administration, Rockville, MD, USA (2004).